Human ovarian carcinoma cells

Histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis

Noriyuki Takai, Norihiko Kawamata, Dorina Gui, Jonathan W. Said, Isao Miyakawa, H. Phillip Koeffler

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

BACKGROUND. Histone deacetylase inhibitors (HDACIs) can inhibit proliferation, stimulate apoptosis, and induce cell cycle arrest in malignant cells. METHODS. The authors investigated the effects of four HDACIs on nine ovarian carcinoma cell lines in vitro and in vivo. Ovarian carcinoma cells were treated with a variety of HDACIs, and their effects on cell growth, the cell cycle, apoptosis, and related events were investigated. The ability of valproic acid (VPA) to inhibit the growth of ovarian tumors in immunodeficient mice was also assessed. RESULTS. Clonogenic assays showed that all ovarian carcinoma cell lines were sensitive to the growth-inhibitory effects of the HDACIs. Cell cycle analysis indicated that their exposure to HDACIs decreased the proportion of cells in S phase and increased the proportion of cells in the G 0/G1 and/or G2/M phases of the cell cycle. Terminal deoxynucleotidyltransferase-mediated uridine triphosphate end-labeling assays demonstrated that HDACIs induced apoptosis, which occurred in concert with alterations in the expression of genes related to apoptosis, cell growth, and malignant phenotype, including the activation of caspase-9 and caspase-3. Chromatin immunoprecipitation analysis revealed a notable increase in levels of acetylated histones associated with the p21 promoter after treatment with suberoylanilide bishydroxamine. In addition, in experiments involving nude mice, VPA significantly inhibited human ovarian tumor growth without toxic side effects. CONCLUSIONS. The results of the current study suggest that HDACIs may be particularly effective in the treatment of ovarian tumors.

Original languageEnglish (US)
Pages (from-to)2760-2770
Number of pages11
JournalCancer
Volume101
Issue number12
DOIs
StatePublished - Dec 15 2004
Externally publishedYes

Fingerprint

Histone Deacetylase Inhibitors
Apoptosis
Carcinoma
Growth
Cell Cycle
Valproic Acid
Cell Line
Neoplasms
Gastrin-Secreting Cells
Uridine Triphosphate
DNA Nucleotidylexotransferase
Caspase 9
Chromatin Immunoprecipitation
G2 Phase
Poisons
Cell Cycle Checkpoints
S Phase
Nude Mice
Caspase 3
Cell Division

Keywords

  • Acetylation
  • Apoptosis
  • Cell cycle
  • Ovarian carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Human ovarian carcinoma cells : Histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. / Takai, Noriyuki; Kawamata, Norihiko; Gui, Dorina; Said, Jonathan W.; Miyakawa, Isao; Koeffler, H. Phillip.

In: Cancer, Vol. 101, No. 12, 15.12.2004, p. 2760-2770.

Research output: Contribution to journalArticle

Takai, Noriyuki ; Kawamata, Norihiko ; Gui, Dorina ; Said, Jonathan W. ; Miyakawa, Isao ; Koeffler, H. Phillip. / Human ovarian carcinoma cells : Histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. In: Cancer. 2004 ; Vol. 101, No. 12. pp. 2760-2770.
@article{2708521cc05e4789a2ef870aa6edd132,
title = "Human ovarian carcinoma cells: Histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis",
abstract = "BACKGROUND. Histone deacetylase inhibitors (HDACIs) can inhibit proliferation, stimulate apoptosis, and induce cell cycle arrest in malignant cells. METHODS. The authors investigated the effects of four HDACIs on nine ovarian carcinoma cell lines in vitro and in vivo. Ovarian carcinoma cells were treated with a variety of HDACIs, and their effects on cell growth, the cell cycle, apoptosis, and related events were investigated. The ability of valproic acid (VPA) to inhibit the growth of ovarian tumors in immunodeficient mice was also assessed. RESULTS. Clonogenic assays showed that all ovarian carcinoma cell lines were sensitive to the growth-inhibitory effects of the HDACIs. Cell cycle analysis indicated that their exposure to HDACIs decreased the proportion of cells in S phase and increased the proportion of cells in the G 0/G1 and/or G2/M phases of the cell cycle. Terminal deoxynucleotidyltransferase-mediated uridine triphosphate end-labeling assays demonstrated that HDACIs induced apoptosis, which occurred in concert with alterations in the expression of genes related to apoptosis, cell growth, and malignant phenotype, including the activation of caspase-9 and caspase-3. Chromatin immunoprecipitation analysis revealed a notable increase in levels of acetylated histones associated with the p21 promoter after treatment with suberoylanilide bishydroxamine. In addition, in experiments involving nude mice, VPA significantly inhibited human ovarian tumor growth without toxic side effects. CONCLUSIONS. The results of the current study suggest that HDACIs may be particularly effective in the treatment of ovarian tumors.",
keywords = "Acetylation, Apoptosis, Cell cycle, Ovarian carcinoma",
author = "Noriyuki Takai and Norihiko Kawamata and Dorina Gui and Said, {Jonathan W.} and Isao Miyakawa and Koeffler, {H. Phillip}",
year = "2004",
month = "12",
day = "15",
doi = "10.1002/cncr.20709",
language = "English (US)",
volume = "101",
pages = "2760--2770",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Human ovarian carcinoma cells

T2 - Histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis

AU - Takai, Noriyuki

AU - Kawamata, Norihiko

AU - Gui, Dorina

AU - Said, Jonathan W.

AU - Miyakawa, Isao

AU - Koeffler, H. Phillip

PY - 2004/12/15

Y1 - 2004/12/15

N2 - BACKGROUND. Histone deacetylase inhibitors (HDACIs) can inhibit proliferation, stimulate apoptosis, and induce cell cycle arrest in malignant cells. METHODS. The authors investigated the effects of four HDACIs on nine ovarian carcinoma cell lines in vitro and in vivo. Ovarian carcinoma cells were treated with a variety of HDACIs, and their effects on cell growth, the cell cycle, apoptosis, and related events were investigated. The ability of valproic acid (VPA) to inhibit the growth of ovarian tumors in immunodeficient mice was also assessed. RESULTS. Clonogenic assays showed that all ovarian carcinoma cell lines were sensitive to the growth-inhibitory effects of the HDACIs. Cell cycle analysis indicated that their exposure to HDACIs decreased the proportion of cells in S phase and increased the proportion of cells in the G 0/G1 and/or G2/M phases of the cell cycle. Terminal deoxynucleotidyltransferase-mediated uridine triphosphate end-labeling assays demonstrated that HDACIs induced apoptosis, which occurred in concert with alterations in the expression of genes related to apoptosis, cell growth, and malignant phenotype, including the activation of caspase-9 and caspase-3. Chromatin immunoprecipitation analysis revealed a notable increase in levels of acetylated histones associated with the p21 promoter after treatment with suberoylanilide bishydroxamine. In addition, in experiments involving nude mice, VPA significantly inhibited human ovarian tumor growth without toxic side effects. CONCLUSIONS. The results of the current study suggest that HDACIs may be particularly effective in the treatment of ovarian tumors.

AB - BACKGROUND. Histone deacetylase inhibitors (HDACIs) can inhibit proliferation, stimulate apoptosis, and induce cell cycle arrest in malignant cells. METHODS. The authors investigated the effects of four HDACIs on nine ovarian carcinoma cell lines in vitro and in vivo. Ovarian carcinoma cells were treated with a variety of HDACIs, and their effects on cell growth, the cell cycle, apoptosis, and related events were investigated. The ability of valproic acid (VPA) to inhibit the growth of ovarian tumors in immunodeficient mice was also assessed. RESULTS. Clonogenic assays showed that all ovarian carcinoma cell lines were sensitive to the growth-inhibitory effects of the HDACIs. Cell cycle analysis indicated that their exposure to HDACIs decreased the proportion of cells in S phase and increased the proportion of cells in the G 0/G1 and/or G2/M phases of the cell cycle. Terminal deoxynucleotidyltransferase-mediated uridine triphosphate end-labeling assays demonstrated that HDACIs induced apoptosis, which occurred in concert with alterations in the expression of genes related to apoptosis, cell growth, and malignant phenotype, including the activation of caspase-9 and caspase-3. Chromatin immunoprecipitation analysis revealed a notable increase in levels of acetylated histones associated with the p21 promoter after treatment with suberoylanilide bishydroxamine. In addition, in experiments involving nude mice, VPA significantly inhibited human ovarian tumor growth without toxic side effects. CONCLUSIONS. The results of the current study suggest that HDACIs may be particularly effective in the treatment of ovarian tumors.

KW - Acetylation

KW - Apoptosis

KW - Cell cycle

KW - Ovarian carcinoma

UR - http://www.scopus.com/inward/record.url?scp=10044225745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10044225745&partnerID=8YFLogxK

U2 - 10.1002/cncr.20709

DO - 10.1002/cncr.20709

M3 - Article

VL - 101

SP - 2760

EP - 2770

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -